Today's Daily Dose brings you news about the FDA rejecting Adamis Pharma's ZIMHI high-dose naloxone injection, proposed for the reversal of opioid overdose; ChemoCentryx' ANCA-associated vasculitis trial results; CymaBay pulling the plug on Seladelpar trials; Global Blood Therapeutics's scoring FDA nod for sickle cell disease drug, and Zogenix upcoming catalyst in March, among others.
from RTT - Biotech https://ift.tt/35FVT2x
via IFTTT
No comments:
Post a Comment